Quick Answer
Serina Therapeutics, Inc. reported Total Revenue of $130.0 thousand for fiscal year 2025.
Serina Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $130.0K +132.1% |
$56.0K -98.2% |
$3.15M +9173.5% |
$34.0K -76.4% |
$144.0K -60.1% |
$361.0K -79.1% |
| Revenue (ASC 606) | $130.0K +132.1% |
$56.0K -98.2% |
$3.15M +9173.5% |
$34.0K -76.4% |
$144.0K -60.1% |
$361.0K -79.1% |
| Net Income | -$19.18M -72.2% |
-$11.14M -311.4% |
$5.27M +150.4% |
-$10.46M -20.6% |
-$8.68M -533.8% |
$2.00M +116.5% |
| Diluted EPS | -$1.91 -26.5% |
-$1.51 -306.8% |
$0.73 +107.5% |
-$9.70 | — | — |
| Total Assets | $6.95M +3.4% |
$6.72M -25.0% |
$8.97M +176.7% |
$3.24M +2.8% |
$3.15M -19.6% |
$3.92M -47.3% |
| Cash and Equivalents | $3.06M -16.8% |
$3.67M -51.8% |
$7.62M +1081.2% |
$645.0K +10.4% |
$584.0K +10.8% |
$527.0K -77.6% |
| Stockholders Equity | -$37.0K -105.8% |
$641.0K +102.0% |
-$32.29M -87.6% |
-$17.21M -45.5% |
-$11.83M -131.3% |
-$5.12M -330.7% |
| R&D Expense | $13.15M +75.9% |
$7.48M +213.2% |
$2.39M +133.0% |
$1.02M -29.6% |
$1.46M -60.8% |
$3.71M -37.1% |
| Operating Income | -$24.02M -40.9% |
-$17.05M -444.8% |
-$3.13M +55.1% |
-$6.97M +12.1% |
-$7.93M +21.5% |
-$10.10M +19.6% |
| Gross Profit | — | — | $102.0K +385.7% |
$21.0K -83.2% |
$125.0K -62.7% |
$335.0K -77.4% |
| Shares Outstanding | 10.77M +28.0% |
8.41M +249.1% |
2.41M +123.4% |
1.08M -97.2% |
37.94M +0.7% |
37.69M +0.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Net Income | September 30, 2025 | -$4.58M | -425.2% | +28.9% |
| Diluted EPS | September 30, 2025 | -$0.45 | -446.2% | +31.8% |
| Total Assets | September 30, 2025 | $12.41M | +67.0% | +38.8% |
| Cash and Equivalents | September 30, 2025 | $8.62M | +170.6% | +42.7% |
| Stockholders Equity | September 30, 2025 | $1.76M | +112.8% | -2.3% |
| R&D Expense | September 30, 2025 | $3.65M | +51.2% | +15.8% |
| Operating Income | September 30, 2025 | -$6.39M | -20.3% | -14.9% |
| Gross Profit | September 30, 2023 | $34.0K | +750.0% | +750.0% |
| Shares Outstanding | September 30, 2025 | 10.54M | +18.6% | +3.9% |
- Serina Therapeutics, Inc. reported Total Revenue of $130.0 thousand for fiscal year 2025.
- Serina Therapeutics, Inc. showed an increase of +132.1% in Total Revenue compared to the prior fiscal year.
- Serina Therapeutics, Inc. reported Revenue (ASC 606) of $130.0 thousand for fiscal year 2025.
- Serina Therapeutics, Inc. showed an increase of +132.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Serina Therapeutics, Inc. reported Net Income of -$19.18 million for fiscal year 2025.
- Serina Therapeutics, Inc. showed a decrease of -72.2% in Net Income compared to the prior fiscal year.
- Serina Therapeutics, Inc. reported Diluted EPS of $1.91 per share (loss) for fiscal year 2025.
- Serina Therapeutics, Inc. showed a decrease of -26.5% in Diluted EPS compared to the prior fiscal year.
- Serina Therapeutics, Inc. reported Total Assets of $6.95 million for fiscal year 2025.
- Serina Therapeutics, Inc. showed an increase of +3.4% in Total Assets compared to the prior fiscal year.
- Serina Therapeutics, Inc. reported Cash and Equivalents of $3.06 million for fiscal year 2025.
- Serina Therapeutics, Inc. showed a decrease of -16.8% in Cash and Equivalents compared to the prior fiscal year.
- Serina Therapeutics, Inc. reported Stockholders Equity of -$37.0 thousand for fiscal year 2025.
- Serina Therapeutics, Inc. showed a decrease of -105.8% in Stockholders Equity compared to the prior fiscal year.
- Serina Therapeutics, Inc. reported R&D Expense of $13.15 million for fiscal year 2025.
- Serina Therapeutics, Inc. showed an increase of +75.9% in R&D Expense compared to the prior fiscal year.
- Serina Therapeutics, Inc. reported Operating Income of -$24.02 million for fiscal year 2025.
- Serina Therapeutics, Inc. showed a decrease of -40.9% in Operating Income compared to the prior fiscal year.
- Serina Therapeutics, Inc. reported Gross Profit of $102.0 thousand for fiscal year 2023.
- Serina Therapeutics, Inc. showed an increase of +385.7% in Gross Profit compared to the prior fiscal year.
- Serina Therapeutics, Inc. reported Shares Outstanding of 10.77 million shares for fiscal year 2025.
- Serina Therapeutics, Inc. showed an increase of +14.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: